Univest
Univest
  • Markets

4 Smallcap Revenue Compounders Quarterly Sales and Profit Growth Stocks to Watch for Future Multibagger Potential: Emmvee, Happy Forgings, Vijaya Diagnostic and Avalon

  • November 16, 2026
  • Posted by: Manan Bisht
  • Category: Best Stocks
No Comments
4 Smallcap Revenue Compounders Quarterly Sales and Profit Growth Stocks to Watch for Future Multibagger Potential: Emmvee, Happy Forgings, Vijaya Diagnostic and Avalon

Emmvee Rs 277.09. Happy Forgings Rs 1,955.80. Vijaya Diagnostic Rs 1,410.10. Avalon Rs 2,038.30. Market caps from Rs 13,616 crore to Rs 19,175 crore. Data as of 13 Nov 2026.

Quick Answer

Emmvee, Happy Forgings, Vijaya Diagnostic and Avalon are the 4 picks in this revenue compounders quarterly sales and profit growth stocks watchlist, with market caps between Rs 13,616 crore and Rs 19,175 crore. Emmvee stands out for the highest return on equity at 32.31%, while Emmvee offers the lowest PE of the group at 13.52. PE ratios run from 13.52 to 91.72, so compare each one with its industry PE before investing. All figures are as of 13 November 2026.

Revenue compounders quarterly sales and profit growth stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. Emmvee, Happy Forgings, Vijaya Diagnostic and Avalon meet that test, with market caps from Rs 13,616 crore to Rs 19,175 crore and Emmvee offering the highest return on equity at 32.31%. Each of these companies has a four-year revenue CAGR of at least 15 per cent, latest-quarter revenue growth of at least 15 per cent year on year, latest-quarter net profit growth of at least 20 per cent year on year, a return on equity of at least 10 per cent, net profit growth in FY26 and in the latest quarter, and market capitalisation below Rs 30,000 crore.

This list covers sales compounders with rising quarterly sales and profit, ranked by market capitalisation. Every company has complete, verifiable financials, and investors screening revenue compounders quarterly sales and profit growth stocks usually begin with size and balance sheet strength, so this list follows the same logic. All figures are as of 13 November 2026 and are drawn from NSE and BSE data and company filings.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • What Are Revenue Compounders Quarterly Sales and Profit Growth Stocks and Why Do They Attract Multibagger Interest?
  • Revenue Compounders Quarterly Sales and Profit Growth Stocks at a Glance: Price, Market Cap, PE and ROE
  • Emmvee: 73.18% Revenue CAGR Since FY22
  • Happy Forgings: 16.16% Revenue CAGR Since FY22
  • Vijaya Diagnostic: 15.13% Revenue CAGR Since FY22
  • Avalon: 17.66% Revenue CAGR Since FY22
  • Revenue Compounders Quarterly Sales and Profit Growth Stocks: Financial Comparison on Growth and Margins
  • Institutional Holding in Emmvee, Happy Forgings, Vijaya Diagnostic and Avalon
  • Risks to Weigh in Revenue Compounders Quarterly Sales and Profit Growth Stocks
  • How to Choose Between Revenue Compounders Quarterly Sales and Profit Growth Stocks
  • Conclusion
  • Frequently Asked Questions on Revenue Compounders Quarterly Sales and Profit Growth Stocks to Watch
    • Which are the best revenue compounders quarterly sales and profit growth stocks to watch for multibagger potential?
    • Is Emmvee a good stock for long-term investors?
    • Can Emmvee become a multibagger from here?
    • What is the market cap of Emmvee, Happy Forgings, Vijaya Diagnostic and Avalon?
    • What are the risks of investing in revenue compounders quarterly sales and profit growth stocks?
    • Why is Avalon trading at a PE of 91.72?
    • How much do institutions hold in Emmvee, Happy Forgings, Vijaya Diagnostic and Avalon?

What Are Revenue Compounders Quarterly Sales and Profit Growth Stocks and Why Do They Attract Multibagger Interest?

Revenue compounders quarterly sales and profit growth stocks are shares of companies that clear several growth and quality tests at once: a four-year revenue CAGR of at least 15 per cent, latest-quarter revenue growth of at least 15 per cent year on year and latest-quarter net profit growth of at least 20 per cent year on year. The 4 here cover diagnostics, electronics manufacturing, forgings and solar manufacturing.

A multi-year growth record together with a strong latest year and a rising latest quarter shows that demand for the business is steady and not a one-off spike. Within revenue compounders quarterly sales and profit growth stocks, all 4 companies show rising profit in FY26 and in the latest quarter, which is the first check most investors make. With revenue compounders quarterly sales and profit growth stocks, comparing valuation, growth and balance sheet strength together works better than relying on one number. Anyone shortlisting revenue compounders quarterly sales and profit growth stocks should compare valuation, growth and balance sheet strength together rather than relying on one number. Read each company’s latest results and exchange filings before acting on revenue compounders quarterly sales and profit growth stocks. The figures for revenue compounders quarterly sales and profit growth stocks in this article come from NSE and BSE data and company filings, and they are complete for every name shown. Within revenue compounders quarterly sales and profit growth stocks, the common thread is rising profit backed by complete financial data. Track every result season for revenue compounders quarterly sales and profit growth stocks, because earnings growth is what supports the share price over time.

Revenue Compounders Quarterly Sales and Profit Growth Stocks at a Glance: Price, Market Cap, PE and ROE

Prices are closing prices as of 13 November 2026. Emmvee has the lowest PE of the group at 13.52, while Emmvee posts the highest return on equity at 32.31%.

Stock CMP (Rs) Market Cap (Rs Cr) PE Industry PE ROE Price to Book Dividend Yield
Emmvee Photovoltaic Power 277.09 19,175 13.52 43.77 32.31% 4.37 0.36%
Happy Forgings 1,955.80 18,441 52.47 48.75 15.38% 8.07 0.20%
Vijaya Diagnostic Centre 1,410.10 14,528 71.31 62.49 19.26% 13.74 0.14%
Avalon Technologies 2,038.30 13,616 91.72 46.61 18.62% 17.08 0.00%

Emmvee: 73.18% Revenue CAGR Since FY22

Emmvee Photovoltaic Power makes solar cells and solar modules at its plants in Karnataka. It reported FY26 revenue of Rs 5,103.39 crore, up 116.22% year on year, and net profit of Rs 1,081.55 crore, up 193.10%. Net profit has compounded at 204.26% a year since FY22, while revenue has grown 73.18% a year. Operating margin was 35.40% in FY26. The debt-to-equity ratio is 0.25, which keeps interest costs low.

In the September 2026 quarter, revenue rose 37.37% to Rs 1,578.90 crore and net profit grew 60.62% to Rs 382.05 crore. Promoters hold 80.03% and FII and DII together hold 12.00% as of September 2026. The stock trades at a PE of 13.52 against an industry PE of 43.77, below the sector average, with a return on equity of 32.31% and a price to book of 4.37.

Happy Forgings: 16.16% Revenue CAGR Since FY22

Happy Forgings makes complex, safety-critical forged and machined components for commercial vehicles, passenger vehicles, tractors and industrial customers. It reported FY26 revenue of Rs 1,577.15 crore, up 9.04% year on year, and net profit of Rs 301.63 crore, up 12.78%. Net profit has compounded at 20.66% a year since FY22, while revenue has grown 16.16% a year. Operating margin was 32.43% in FY26. The debt-to-equity ratio is 0.24, which keeps interest costs low.

In the September 2026 quarter, revenue rose 32.69% to Rs 509.05 crore and net profit grew 32.76% to Rs 97.50 crore. Promoters hold 78.44% and FII and DII together hold 17.30% as of September 2026. The stock trades at a PE of 52.47 against an industry PE of 48.75, with a return on equity of 15.38% and a price to book of 8.07.

Vijaya Diagnostic: 15.13% Revenue CAGR Since FY22

Vijaya Diagnostic Centre runs diagnostic centres offering pathology and radiology services, with a strong base in South India. It reported FY26 revenue of Rs 835 crore, up 19.34% year on year, and net profit of Rs 172.98 crore, up 20.30%. Net profit has compounded at 11.81% a year since FY22, while revenue has grown 15.13% a year. Operating margin was 43.94% in FY26.

In the September 2026 quarter, revenue rose 25.28% to Rs 260.34 crore and net profit grew 37.41% to Rs 59.47 crore. Domestic institutions raised their holding from 25.34% in September 2025 to 32.50% in September 2026. The stock trades at a PE of 71.31 against an industry PE of 62.49, with a return on equity of 19.26% and a price to book of 13.74.

Avalon: 17.66% Revenue CAGR Since FY22

Avalon Technologies is an electronics manufacturing services provider for industrial, clean energy, mobility and healthcare customers in India and the US. It reported FY26 revenue of Rs 1,632.13 crore, up 46.35% year on year, and net profit of Rs 112.95 crore, up 78.04%. Net profit has compounded at 13.75% a year since FY22, while revenue has grown 17.66% a year. Operating margin was 12.62% in FY26.

In the September 2026 quarter, revenue rose 35.30% to Rs 528.17 crore and net profit grew 59.49% to Rs 39.84 crore. Foreign investors raised their holding from 10.04% in September 2025 to 11.13% in September 2026. The stock trades at a PE of 91.72 against an industry PE of 46.61, with a return on equity of 18.62% and a price to book of 17.08.

Revenue Compounders Quarterly Sales and Profit Growth Stocks: Financial Comparison on Growth and Margins

The table compares scale and growth across these revenue compounders quarterly sales and profit growth stocks. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.

Stock Revenue (Rs Cr) Net Profit (Rs Cr) Revenue Growth (YoY) 4-Year Revenue CAGR 4-Year Net Profit CAGR Latest Quarter Profit Growth (YoY)
Emmvee 5,103.39 1,081.55 116.22% 73.18% 204.26% 60.62%
Happy Forgings 1,577.15 301.63 9.04% 16.16% 20.66% 32.76%
Vijaya Diagnostic 835 172.98 19.34% 15.13% 11.81% 37.41%
Avalon 1,632.13 112.95 46.35% 17.66% 13.75% 59.49%

Check the Univest Screener for live data on these revenue compounders quarterly sales and profit growth stocks

Institutional Holding in Emmvee, Happy Forgings, Vijaya Diagnostic and Avalon

Institutional holding shows who is backing these revenue compounders quarterly sales and profit growth stocks alongside the promoter. The table uses the latest reported quarter for each. Vijaya Diagnostic has the deepest institutional backing, with FII and DII together holding 43.16% as of September 2026. Domestic institutions increased their holding over the past year in Vijaya Diagnostic (from 25.34% to 32.50%). To see how this group fits the wider market, many investors compare it with the Nifty Smallcap 100.

Stock Promoter FII DII Public Quarter
Emmvee 80.03% 2.19% 9.81% 7.97% September 2026
Happy Forgings 78.44% 2.37% 14.93% 4.26% September 2026
Vijaya Diagnostic 52.46% 10.66% 32.50% 4.38% September 2026
Avalon 40.35% 11.13% 19.96% 28.57% September 2026

Risks to Weigh in Revenue Compounders Quarterly Sales and Profit Growth Stocks

Being careful with revenue compounders quarterly sales and profit growth stocks means looking at what can slow the story as well as what can speed it up. Four points matter most:

  • Past growth may not repeat.
  • Share prices can move sharply in either direction.
  • Valuation: Avalon trades at a PE of 91.72 against an industry PE of 46.61, so earnings need to keep growing to support the price.
  • Concentration: Holding all 4 names puts the allocation in one theme, so size each position to match your risk appetite.

How to Choose Between Revenue Compounders Quarterly Sales and Profit Growth Stocks

Picking from revenue compounders quarterly sales and profit growth stocks comes down to four checks, applied in order.

  1. Check balance sheet strength first, and prefer a debt-to-equity ratio below 1 for non-financial companies.
  2. Compare each PE with the industry PE (43.77 to 62.49) and ask whether the growth rate justifies any gap.
  3. Track net profit growth, the operating margin and the return on equity in every quarterly result.
  4. Stagger entries across quarters and review institutional holding every reporting season.

Download the Univest iOS App or Univest Android App to track Emmvee, Happy Forgings, Vijaya Diagnostic and Avalon live prices.

Conclusion

Among revenue compounders quarterly sales and profit growth stocks, Emmvee stands out for the highest return on equity at 32.31%, Emmvee for the lowest PE of the group at 13.52, Emmvee for the fastest profit compounding at 204.26% a year since FY22 and Emmvee for the sharpest latest-quarter profit growth at 60.62%. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing revenue compounders quarterly sales and profit growth stocks should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions on Revenue Compounders Quarterly Sales and Profit Growth Stocks to Watch

Which are the best revenue compounders quarterly sales and profit growth stocks to watch for multibagger potential?

Ans. Emmvee, Happy Forgings, Vijaya Diagnostic and Avalon are the 4 names this list highlights, with market caps of Rs 19,175 crore, Rs 18,441 crore, Rs 14,528 crore and Rs 13,616 crore respectively. Emmvee is notable for the highest return on equity at 32.31%. Emmvee stands out for the lowest PE of the group at 13.52. Emmvee offers the fastest profit growth, 204.26% a year since FY22. Emmvee brings the sharpest latest-quarter profit growth at 60.62%. These are watchlist names for revenue compounders quarterly sales and profit growth stocks, not recommendations, so match each one to your own risk profile and time horizon.

Is Emmvee a good stock for long-term investors?

Ans. Emmvee has a return on equity of 32.31%, a PE of 13.52 against an industry PE of 43.77 and a market cap of Rs 19,175 crore. Net profit has compounded at 204.26% a year since FY22, and FY26 revenue rose 116.22% while September 2026 quarter net profit grew 60.62%. Long-term returns in revenue compounders quarterly sales and profit growth stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.

Can Emmvee become a multibagger from here?

Ans. A multibagger outcome in revenue compounders quarterly sales and profit growth stocks requires earnings to keep growing faster than the market for several years. Emmvee has grown revenue at 73.18% a year since FY22 and net profit at 204.26% a year, and FY26 revenue rose 116.22%. At a PE of 13.52 against an industry PE of 43.77, valuation should be checked against that growth before investing, and no outcome is guaranteed.

What is the market cap of Emmvee, Happy Forgings, Vijaya Diagnostic and Avalon?

Ans. As of 13 November 2026, Emmvee has a market cap of Rs 19,175 crore, Happy Forgings has a market cap of Rs 18,441 crore, Vijaya Diagnostic has a market cap of Rs 14,528 crore and Avalon has a market cap of Rs 13,616 crore. All of them qualify as smallcaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on revenue compounders quarterly sales and profit growth stocks.

What are the risks of investing in revenue compounders quarterly sales and profit growth stocks?

Ans. The main risks are market swings, slower growth than expected and valuations that already reflect good news. Companies with strong balance sheets and steady earnings handle these better. Avalon trades at a PE of 91.72 against an industry PE of 46.61, so earnings growth needs to hold up. Diversifying across the 4 names and reviewing each quarterly result helps keep risk in check.

Why is Avalon trading at a PE of 91.72?

Ans. Avalon’s PE of 91.72 compares with an industry PE of 46.61. The market is paying a premium for a return on equity of 18.62%, profit growth of 13.75% a year since FY22 and latest-quarter profit growth of 59.49%, which also means the stock is more sensitive if growth slows. Investors in revenue compounders quarterly sales and profit growth stocks who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.

How much do institutions hold in Emmvee, Happy Forgings, Vijaya Diagnostic and Avalon?

Ans. As of the latest reported quarter, FII and DII together hold 12.00% of Emmvee (2.19% and 9.81%), 17.30% of Happy Forgings (2.37% and 14.93%), 43.16% of Vijaya Diagnostic (10.66% and 32.50%) and 31.09% of Avalon (11.13% and 19.96%). Rising institutional holding is a useful signal in revenue compounders quarterly sales and profit growth stocks, though it should be read with earnings trends rather than on its own.



revenue compounders quarterly sales and profit growth stocks smallcap revenue compounders quarterly sales and profit growth stocks
Author: Manan Bisht
Manan Bisht is a Financial Content Writer at Univest, covering Indian equity markets with a focus on investor education, stock analysis, and personal finance. With over a year of hands-on experience in financial content creation, he translates complex market concepts into clear, beginner-friendly articles for retail investors. He holds a Bachelor of Commerce (B.Com) from Delhi University, giving him a strong academic grounding in financial accounting, economics, business law, and capital markets. This foundation shapes how he approaches every article — grounding analysis in verified financial fundamentals rather than speculation. He is also a SEBI Investor Certification holder, reinforcing his understanding of securities markets, investor rights, and SEBI regulatory frameworks — directly relevant to the YMYL (Your Money, Your Life) content he publishes. All articles are reviewed by Univest's in-house equity research team, led by Ankit Jaiswal, Senior Research Analyst, to meet SEBI editorial standards.

Leave a Reply Cancel reply